News Italian decision sets up launch of Oncopeptides' Pepaxti Oncopeptides hopes to reignite growth in multiple myeloma drug Pepaxti after getting reimbursement approval in Italy.
News Oncopeptides gets EU nod for myeloma drug Pepaxti ahead of U... The European Commission has approved Oncopeptides' Pepaxti in combination with dexamethasone for multiple myeloma patients with so-called triple class refractory disease – in other words th
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.